https://www.selleckchem.com/pr....oducts/trilaciclib.h
In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on L-arginine (Arg) related risk markers asymmetric and symmetric dimethylarginine (ADMA and SDMA) and the protective biomarker L-homoarginine (hArg) linking T2D to cardiovascular and renal disease have not yet been reported. Plasma and 24-h urine samples taken before and after 6weeks of treatment were available from two prospective, randomized, double-blind,
Me gusta
Comentario
Compartir
